lapatinib has been researched along with alfuzosin in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (alfuzosin) | Trials (alfuzosin) | Recent Studies (post-2010) (alfuzosin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 427 | 127 | 120 |
| Protein | Taxonomy | lapatinib (IC50) | alfuzosin (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 0.018 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.023 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bansal, R; Malhotra, A | 1 |
2 review(s) available for lapatinib and alfuzosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |